You have free access to this content

Cancer

Cover image for Cancer

1 July 2010

Volume 116, Issue 13

Pages 3075–3305

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Correspondence
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
  2. Editorials

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Correspondence
    1. You have free access to this content
      Myth: We can tailor palliative care to match life expectancy. Reality: No we can't (pages 3078–3079)

      William F. Hartsell

      Article first published online: 19 APR 2010 | DOI: 10.1002/cncr.25118

      The goal of palliative therapy is to palliate, not to cure. For the best palliative results for our patients (and their caregivers), this should be done as rapidly as possible.

    2. You have free access to this content
      Early 21st Century renal cell carcinoma : A “paradigm shift” (pages 3080–3083)

      Massimo Lazzeri and Giorgio Guazzoni

      Article first published online: 13 APR 2010 | DOI: 10.1002/cncr.25021

      Individuals involved in the management of patients with small renal masses should acknowledge the role and the importance of active surveillance in older populations (aged >75 years) and minimally invasive ablative therapies. These new therapeutic strategies should be inculcated during medical training and practice so that they may become just as embedded as the emphasis on the oncologic outcome of standard treatment.

  3. Original Articles

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Correspondence
    1. Disease Site

      Breast Disease
      You have free access to this content
      Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy : A Single-Institution Review (pages 3084–3092)

      Shaheenah Dawood, Ana M. Gonzalez-Angulo, Constance Albarracin, Tse Kuan Yu, Gabriel N. Hortobagyi, Thomas A. Buchholz and Wendy A. Woodward

      Article first published online: 19 APR 2010 | DOI: 10.1002/cncr.25115

      Breast tumor subtype has a significant prognostic role among women with breast cancer and brain metastases. In addition, in the trastuzumab era factors such as recursive partitioning analysis and adequate radiation dose continue to be important prognostic factors.

    2. You have free access to this content
      Is it useful to detect lymphovascular invasion in lymph node-positive patients with primary operable breast cancer? (pages 3093–3101)

      Florence Ragage, Marc Debled, Gaëtan MacGrogan, Véronique Brouste, Marie Desrousseaux, Isabelle Soubeyran, Christine Tunon de Lara, Louis Mauriac and Isabelle de Mascarel

      Article first published online: 21 APR 2010 | DOI: 10.1002/cncr.25137

      Lymphovascular invasion is an independent prognostic factor in lymph node-positive breast cancer. This pathological factor contributes to separate subgroups with highly distinct prognoses.

    3. You have free access to this content
      Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment : A prospective study (pages 3102–3111)

      Paniti Sukumvanich, L. Doug Case, Kimberly Van Zee, S. Eva Singletary, Electra D. Paskett, Jeanne A. Petrek, Elizabeth Naftalis and Michelle J. Naughton

      Article first published online: 9 APR 2010 | DOI: 10.1002/cncr.25106

      A considerable proportion of women treated with chemotherapy will experience periods of chemotherapy-induced amenorrhea, but many will resume bleeding. Newer treatment regimens such as doxorubicin, cyclophosphamide, and paclitaxel appear to have a higher resumption of bleeding compared with the combination of cyclophosphamide, methotrexate, and 5-fluorouracil.

    4. You have free access to this content
      Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population (pages 3112–3118)

      Masakazu Toi, Hiroji Iwata, Takeharu Yamanaka, Norikazu Masuda, Shinji Ohno, Seigo Nakamura, Takahiro Nakayama, Masahiro Kashiwaba, Shunji Kamigaki and Katsumasa Kuroi

      Article first published online: 9 APR 2010 | DOI: 10.1002/cncr.25206

      In a retrospective study of 200 lymph node-negative and estrogen receptor-positive patients with primary breast cancer who were treated with tamoxifen, the 21-gene signature showed a significant value for predicting recurrence and death. This is the first study in the Asian population.

    5. Genitourinary Disease
      You have free access to this content
      Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older (pages 3119–3126)

      Brian R. Lane, Robert Abouassaly, Tianming Gao, Christopher J. Weight, Adrian V. Hernandez, Benjamin T. Larson, Jihad H. Kaouk, Inderbir S. Gill and Steven C. Campbell

      Article first published online: 10 MAY 2010 | DOI: 10.1002/cncr.25184

      In patients aged ≥75 years, surgical management of clinically localized renal tumors (by either nephrectomy or any nephron-sparing intervention) was not associated with increased survival after adjusting for age and comorbidity. Patients died mostly of cardiovascular causes, and nephrectomy accelerated renal dysfunction, which was associated with cardiovascular mortality, suggesting the possibility of over treatment in these patients with limited life expectancy.

    6. You have free access to this content
      Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma (pages 3127–3134)

      Surena F. Matin, Vitaly Margulis, Ashish Kamat, Christopher G. Wood, H. Barton Grossman, Gordon A. Brown, Colin P. N. Dinney, Randall Millikan and Arlene O. Siefker-Radtke

      Article first published online: 7 APR 2010 | DOI: 10.1002/cncr.25050

      In patients with high-grade ureteral and renal pelvic transitional cell carcinoma, neoadjuvant chemotherapy was associated with a 14% rate of complete remission and a 41.5% reduction in the incidence of pathologic T3 disease compared with a matched historic group that underwent initial surgery. In the absence of survival data and randomized trials, the current results provided highly relevant data supporting the continued enrollment of patients onto trials that incorporate the neoadjuvant strategy, which allows the optimal administration of cytotoxic chemotherapy.

    7. You have free access to this content
      Durable oncologic outcomes after radiofrequency ablation : Experience from treating 243 small renal masses over 7.5 years (pages 3135–3142)

      Chad R. Tracy, Jay D. Raman, Chester Donnally, Clayton K. Trimmer and Jeffrey A. Cadeddu

      Article first published online: 14 APR 2010 | DOI: 10.1002/cncr.25002

      At a mean follow-up of 27 months in 208 patients (243 masses) who underwent radiofrequency ablation (RFA), the 5-year recurrence-free, cancer-specific, metastasis-free, and overall survival rates were 93%, 99%, 95%, and 85%, respectively. Although longer term follow-up will be required, RFA continues to remain efficacious for the treatment of renal cell carcinoma at 5 years.

    8. Hematologic Malignancies
      You have free access to this content
      Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma : A retrospective study (pages 3143–3151)

      Jonathan L. Kaufman, Ajay Nooka, Mark Vrana, Charise Gleason, L. Thompson Heffner and Sagar Lonial

      Article first published online: 14 APR 2010 | DOI: 10.1002/cncr.25143

      Combined bortezomib, thalidomide, and dexamethasone as induction therapy before autologous stem cell transplantation (ASCT) is a well tolerated and effective therapeutic option for patients with multiple myeloma and is associated with high postinduction and post-ASCT response rates (91% and 100%, respectively). In the current study, these response rates appeared to translate into promising long-term outcomes with similar progression-free and overall survival reported for ASCT and non-ASCT groups.

    9. You have free access to this content
      Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction (pages 3152–3159)

      Wei-Gang Tong, Hagop Kantarjian, Susan O'Brien, Stefan Faderl, Farhad Ravandi, Gautam Borthakur, Jianqin Shan, Sherry Pierce, Mary Beth Rios and Jorge Cortes

      Article first published online: 7 APR 2010 | DOI: 10.1002/cncr.25071

      Patients with chronic myelogenous leukemia who present with pre-existing liver and/or renal dysfunction might have a higher rate of hematologic toxicity and require more frequent dose reductions while treated with imatinib. Most patients can be adequately managed, resulting in response rates and survival similar to those without pre-existing organ dysfunction.

    10. Hepatobiliary Disease
      You have free access to this content
      Polymorphisms in ERCC2, MSH2, and OGG1 DNA repair genes and gallbladder cancer risk in a population of Northern India (pages 3160–3169)

      Kshitij Srivastava, Anvesha Srivastava and Balraj Mittal

      Article first published online: 9 APR 2010 | DOI: 10.1002/cncr.25063

      Genetic variants in the DNA repair pathways may be involved in gallbladder cancer etiology in a North Indian population.

    11. Lung Disease
      You have free access to this content
      Value of integrated positron emission tomography revised using a phantom study to evaluate malignancy grade of lung adenocarcinoma : A multicenter study (pages 3170–3177)

      Haruhiko Nakayama, Sakae Okumura, Hiromitsu Daisaki, Yasufumi Kato, Hirofumi Uehara, Shuji Adachi, Masahiro Yoshimura and Morihito Okada

      Article first published online: 1 APR 2010 | DOI: 10.1002/cncr.25244

      Using phantom studies to overcome difficulties of positron emission tomography (PET)/computed tomography (CT) in a multicenter study, the results of the current study demonstrate that a higher maximum standardized uptake value reflects aggressive malignant behavior in clinical T1N0M0 adenocarcinomas, independent of bronchioloalveolar carcinoma components. Preoperative PET/CT assessment in addition to high-resolution CT could be used to construct hypotheses for a future clinical study of strategies for treating patients with small lung adenocarcinoma.

    12. Melanoma
      You have free access to this content
      Comparison of classification systems in melanoma sentinel lymph nodes—An analysis of 697 patients from a single center (page 3178)

      Andre Meier, Imke Satzger, Bernward Völker, Alexander Kapp and Ralf Gutzmer

      Article first published online: 19 APR 2010 | DOI: 10.1002/cncr.25074

      In the current study, histologic parameters in sentinel lymph nodes and resulting classification systems were used to predict prognosis in patients with melanoma. The combination of 3 different, statistically independent parameters predicted prognosis most precisely.

    13. Sarcoma
      You have free access to this content
      Clinical outcome of children and adults with localized Ewing sarcoma : Impact of Chemotherapy Dose and Timing of Local Therapy (pages 3189–3194)

      Abha A. Gupta, Alberto Pappo, Natasha Saunders, Sevan Hopyan, Peter Ferguson, Jay Wunder, Brian O'Sullivan, Charles Catton, Mark Greenberg and Martin Blackstein

      Article first published online: 13 APR 2010 | DOI: 10.1002/cncr.25144

      Adults with localized Ewing sarcoma are reported to have an inferior outcome compared with pediatric patients. This difference may be related to a lesser dose of alkylating agent and timing of local therapy.

    14. Discipline

      Disparities Research
      You have free access to this content
      Diagnostic and therapeutic delays among a multiethnic sample of breast and cervical cancer survivors (pages 3195–3204)

      Kimlin T. Ashing-Giwa, Patricia Gonzalez, Jung-Won Lim, Cathie Chung, Benjamin Paz, George Somlo and Mark T. Wakabayashi

      Article first published online: 21 APR 2010 | DOI: 10.1002/cncr.25060

      Due in part to a higher proportion of diagnostic and therapeutic delays, ethnic minorities endure greater cancer burden, including poorer survival and survivorship outcomes. The medical community must recognize the impact of existing psychological and cultural dimensions on diagnostic care, as well as the personal and healthcare system level barriers that contribute to therapeutic delays.

    15. You have free access to this content
      Ethnicity and management of colon cancer in New Zealand : Do indigenous patients get a worse deal? (pages 3205–3214)

      Sarah Hill, Diana Sarfati, Tony Blakely, Bridget Robson, Gordon Purdie, Elizabeth Dennett, Donna Cormack, Kevin Dew, John Z. Ayanian and Ichiro Kawachi

      Article first published online: 21 APR 2010 | DOI: 10.1002/cncr.25127

      Significant racial/ethnic differences were observed in the treatment of Maori (indigenous) and non-Maori New Zealanders with colon cancer. Maori patients appeared to receive a lower quality of cancer care, including a higher risk of postoperative death, longer treatment delays, and a lower probability of receiving adjuvant chemotherapy.

    16. You have free access to this content
      Comparative analysis of breast cancer risk factors among hispanic and non-hispanic white women (pages 3215–3223)

      Lisa M. Hines, Betsy Risendal, Martha L. Slattery, Kathy B. Baumgartner, Anna R. Giuliano, Carol Sweeney, Dana E. Rollison and Tim Byers

      Article first published online: 26 APR 2010 | DOI: 10.1002/cncr.25154

      Breast cancer risk factors established among non-Hispanic white populations had less influence on breast cancer risk in Hispanic women. These findings reflect the need to further evaluate breast cancer risk factors among different ethnic and racial populations, which may provide unique insight into the etiology of breast cancer.

    17. Medical Oncology
      You have free access to this content
      Economic evaluation of erythropoiesis-stimulating agents for anemia related to cancer (pages 3224–3232)

      Scott Klarenbach, Braden Manns, Tony Reiman, Martin Neil Reaume, Helen Lee, Anita Lloyd, Natasha Wiebe, Brenda Hemmelgarn and Marcello Tonelli

      Article first published online: 19 APR 2010 | DOI: 10.1002/cncr.25052

      Despite quality of life benefits of erythropoiesis-stimulating agents in cancer patients with anemia, their use is not cost-effective. The conclusions are unaltered when recent guidelines recommending more conservative use are considered.

    18. Pediatric Oncology
      You have free access to this content
      Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo (pages 3233–3243)

      Kristen N. Richards, Patrick A. Zweidler-McKay, Nadine Van Roy, Frank Speleman, Jesus Trevino, Peter E. Zage and Dennis P. M. Hughes

      Article first published online: 19 APR 2010 | DOI: 10.1002/cncr.25073

      Neuroblastoma cell lines and patient samples express the ERBB receptor tyrosine kinases EGFR, HER-4 and, more variably, HER-3 and HER-2. A pan-ERBB inhibitor gave much better neuroblastoma growth inhibition than did an EGFR-specific inhibitor.

    19. You have free access to this content
      Informed consent for pediatric phase 1 cancer trials: Physicians' perspectives (pages 3244–3250)

      Tsiao Yi Yap, Amy D. Yamokoski, Sabahat Hizlan, Stephen J. Zyzanski, Anne L. Angiolillo, Susan R. Rheingold, Justin N. Baker and Eric D. Kodish

      Article first published online: 9 APR 2010 | DOI: 10.1002/cncr.25158

      One key to understanding and ultimately improving the quality of informed consent (IC) for pediatric phase 1 cancer trials is to better understand the views of pediatric oncologists at the nexus of investigational medicine and clinical care. Gaining insights into physicians' experiences with, and opinions of, the IC process in this sensitive context enhances future research and education efforts around this ethically challenging topic.

    20. Radiation Oncology
      You have free access to this content
      Palliative radiotherapy tailored to life expectancy in end-stage cancer patients : Reality or myth? (pages 3251–3256)

      Stephan Gripp, Sibylle Mjartan, Edwin Boelke and Reinhardt Willers

      Article first published online: 12 APR 2010 | DOI: 10.1002/cncr.25112

      Overly optimistic survival estimates and lack of accurate prognostic systems may mislead treatment decisions on palliative radiotherapy for cancer patients at the very end stage, and this may jeopardize potential benefits.

    21. You have free access to this content
      A national propensity-adjusted analysis of adjuvant radiotherapy in the treatment of resected pancreatic adenocarcinoma (pages 3257–3266)

      Theodore P. McDade, Joshua S. Hill, Jessica P. Simons, Bilal Piperdi, Sing Chau Ng, Zheng Zhou, Sidney P. Kadish, Thomas J. Fitzgerald and Jennifer F. Tseng

      Article first published online: 19 APR 2010 | DOI: 10.1002/cncr.25069

      Adjuvant radiotherapy for resected pancreatic adenocarcinoma was associated with a significant survival advantage in this retrospective study using a large, national-level database. This benefit was maintained even when propensity score methods were used to limit selection bias stemming from differences between treatment groups.

    22. Symptom Control and Palliative Care
      You have free access to this content
      Cancer Quality-ASSIST supportive oncology quality indicator set : Feasibility, reliability, and validity testing (pages 3267–3275)

      Sydney M. Dy, Karl A. Lorenz, Sean M. O'Neill, Steven M. Asch, Anne M. Walling, Diana Tisnado, Anna Liza Antonio and Jennifer L. Malin

      Article first published online: 21 APR 2010 | DOI: 10.1002/cncr.25109

      In a pilot evaluation of a comprehensive set of 92 supportive oncology quality indicators, Cancer Quality-ASSIST, the authors found that 41 were sufficiently feasible, reliable, and valid in 2 clinical settings. These include outpatient and hospital indicators for symptoms commonly related to cancer and its treatment and information and care planning.

    23. Translational Research
      You have free access to this content
      Nuclear factor κB transcription factors are coexpressed and convey a poor outcome in ovarian cancer (pages 3276–3284)

      Christina M. Annunziata, Helene Tuft Stavnes, Lilach Kleinberg, Aasmund Berner, Lidia F. Hernandez, Michael J. Birrer, Seth M. Steinberg, Ben Davidson and Elise C. Kohn

      Article first published online: 21 APR 2010 | DOI: 10.1002/cncr.25190

      Recent work has highlighted a role for nuclear factor κB (NF-κB) in the propagation of ovarian cancer cell lines, but the significance and mechanism of NF-κB in ovarian cancer is unknown. The authors uncovered an association between expression of the NF-κB transcription factor p50 and poor overall survival in patients with ovarian cancer; however, paradoxically, matrix metalloproteinase 9 (MMP9) expression had the opposite effect, and patients without MMP9 expression had the poorest prognosis.

    24. Disease Site

      Translational Research
      You have free access to this content
      Radiofrequency field-induced thermal cytotoxicity in cancer cells treated with fluorescent nanoparticles (pages 3285–3293)

      Evan S. Glazer and Steven A. Curley

      Article first published online: 19 APR 2010 | DOI: 10.1002/cncr.25135

      Quantum dots and gold nanoparticles heat in a concentration-dependent manner in noninvasive radiofrequency fields. Antibody targeting allows for significant targeted cancer cell cytotoxicity without bystander cell injury.

    25. You have free access to this content
      1,25D3 Enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models (pages 3294–3303)

      Yingyu Ma, Wei-Dong Yu, Donald L. Trump and Candace S. Johnson

      Article first published online: 13 APR 2010 | DOI: 10.1002/cncr.25059

      The active vitamin D metabolite, 1,25D3, enhanced antitumor activity of a standard chemotherapy regimen for bladder cancer, gemcitabine and cisplatin, in vitro and in vivo. 1,25D3 and gemcitabine and cisplatin induced p73 accumulation, which contributed to the antiproliferative effects of 1,25D3 and gemcitabine and cisplatin.

  4. Correspondence

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Correspondence
    1. You have free access to this content
    2. You have free access to this content

SEARCH

SEARCH BY CITATION